Workflow
金城医药(300233) - 2021 Q3 - 季度财报
300233Jincheng Pharm(300233)2021-10-26 16:00

Revenue and Profit - The company's revenue for Q3 2021 reached ¥800,352,256.80, representing a 20.63% increase year-over-year[4] - Net profit attributable to shareholders was ¥27,334,089.51, a decrease of 29.08% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥16,863,703.00, down 52.32% year-over-year[4] - The net profit attributable to shareholders of the parent company decreased by 42.06% to ¥120,339,441.14 compared to ¥207,683,729.50 in the same period last year, primarily due to increased costs from rising raw material prices and declining market prices in the pharmaceutical intermediate sector[2] - Net profit for the current period was ¥129,756,225.21, a decrease of 39.0% from ¥212,645,545.78 in the previous period[33] - The total comprehensive income for the current period was ¥134,999,223.02, down from ¥212,645,545.78, a decrease of 36.5%[36] Cash Flow - Cash flow from operating activities for the year-to-date was ¥232,213,332.77, reflecting a decline of 47.13% compared to the previous year[4] - The net cash flow from operating activities decreased by 47.13% to ¥232,213,332.77, primarily due to increased procurement expenses and other cash payments related to operating activities[2] - The net cash flow from operating activities was 232.21million,adecreaseof47.2232.21 million, a decrease of 47.2% compared to 439.25 million in the previous period[40] - Cash outflow from operating activities totaled 1.81billion,up24.81.81 billion, up 24.8% from 1.45 billion year-over-year[40] - The net cash flow from investing activities was -64.40million,animprovementfrom64.40 million, an improvement from -199.95 million in the previous period[40] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥5,148,164,473.55, an increase of 2.96% from the end of the previous year[4] - The company's total assets reached CNY 5,148,164,473.55, up from CNY 5,000,113,119.10 at the end of 2020, indicating an increase of about 2.96%[28] - Total liabilities increased to CNY 1,700,120,234.27 from CNY 1,532,815,590.71, representing a rise of approximately 10.9%[26] - The company's total liabilities amounted to 1.15billion,remainingstablecomparedtothepreviousperiod[46]Totalliabilitiesamountedtoapproximately1.53billion,adecreasefrom1.60billion[48]ShareholderEquityThecompanysequityattributabletoshareholderswas¥3,409,070,935.69,showingaslightdecreaseof0.841.15 billion, remaining stable compared to the previous period[46] - Total liabilities amounted to approximately 1.53 billion, a decrease from 1.60 billion[48] Shareholder Equity - The company's equity attributable to shareholders was ¥3,409,070,935.69, showing a slight decrease of 0.84% from the previous year[4] - The total equity attributable to shareholders decreased to CNY 3,409,070,935.69 from CNY 3,437,981,008.87, reflecting a decline of about 0.84%[29] - Total equity attributable to shareholders reached approximately 3.44 billion, unchanged from the previous period[48] Expenses - Total operating costs amounted to ¥1,971,667,778.59, up from ¥1,695,833,016.81, reflecting a year-over-year increase of 16.2%[30] - Research and development expenses increased to ¥112,080,623.84, up from ¥100,869,291.51, marking a rise of 11.9%[30] - Sales expenses rose to ¥590,656,859.04, compared to ¥522,770,987.36, indicating an increase of 13.0%[30] Other Income and Investments - Other income increased by 143.36% to ¥30,590,759.72, mainly due to government subsidies received amounting to ¥12 million during the reporting period[2] - Investment income rose significantly by 782.46% to ¥1,313,414.69, attributed to increased forward exchange gains[2] - The company reported an investment income of ¥1,313,414.69, recovering from a loss of ¥192,452.61 in the previous period[30] Inventory and Receivables - Accounts receivable decreased by 33.17% to ¥462,866,791.73, attributed to increased sales collections[8] - Inventory increased by 34.31% to ¥381,551,096.60, driven by rising raw material prices and increased stockpiling[8] - The company reported a decrease in accounts receivable to CNY 462,866,791.73 from CNY 692,576,369.97, a significant drop of approximately 33.1%[23] - Inventory levels rose to CNY 381,551,096.60, compared to CNY 284,077,327.28 at the end of 2020, marking an increase of approximately 34.4%[23] Borrowings - Short-term borrowings rose by 44.81% to ¥223,000,000.00, reflecting an increase in bank short-term loans[8] - Short-term borrowings rose to CNY 223,000,000.00 from CNY 154,000,000.00, an increase of approximately 45%[26] - The company’s long-term borrowings stood at 255.39 million, unchanged from the previous period[46] Share Repurchase and Minority Interests - The company repurchased shares amounting to ¥120,013,694.64, reflecting a 63.17% increase in treasury stock[2] - Minority interests increased by 89.79% to ¥9,416,784.07, driven by profit growth in the company's controlling subsidiaries[2] Fair Value Changes and Special Reserves - The company recorded a fair value change income of ¥5,400,300.00, resulting from the impact of exchange rate fluctuations on foreign currency receivables[2] - The company’s special reserves increased by 962.23% to ¥3,308,756.89 due to higher provisions during the reporting period[2] Accounting Standards and Audit Status - The company adopted the revised Accounting Standards for Leases from January 1, 2021, impacting the recognition of lease liabilities[50] - The third quarter report was not audited, indicating preliminary financial data[51]